Pathology and Laboratory Medicine

17-30 of 30

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  Wenxin Xu, MD; Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC

  RestartResume

  Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC

  MinuteCE®

  Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC

  Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Interprofessional Coordination of Adverse Event Management

  RestartResume

  Interprofessional Coordination of Adverse Event Management

  MinuteCE®

  Interprofessional Coordination of Adverse Event Management

  Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Recent updates from adjuvant trials in HR+/HER2- EBC

  RestartResume

  Recent updates from adjuvant trials in HR+/HER2- EBC

  MinuteCE®

  Recent updates from adjuvant trials in HR+/HER2- EBC

  Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  MinuteCE®

  Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 credits 10 episodes

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 credits 10 episodes

• 

  RestartResume

  Maximizing Adherence and Persistence via Patient Engagement

  RestartResume

  Maximizing Adherence and Persistence via Patient Engagement

  MinuteCE®

  Maximizing Adherence and Persistence via Patient Engagement

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence

  RestartResume

  Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence

  MinuteCE®

  Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  RestartResume

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  MinuteCE®

  Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  RestartResume

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  MinuteCE®

  Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Treatment Intensification in HR+/HER2- EBC: Who and When?

  RestartResume

  Treatment Intensification in HR+/HER2- EBC: Who and When?

  MinuteCE®

  Treatment Intensification in HR+/HER2- EBC: Who and When?

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens

  RestartResume

  Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens

  MinuteCE®

  Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• 

  RestartResume

  High-Risk, HR+/HER2- EBC: Mastering Treatment Selection

  RestartResume

  High-Risk, HR+/HER2- EBC: Mastering Treatment Selection

  MinuteCE®

  High-Risk, HR+/HER2- EBC: Mastering Treatment Selection

  Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD

  1.25 program credits

  • 

    

    Hope S. Rugo, MD, FASCO

  • 

    

    Nadia Harbeck, MD, PhD

  1.25 program credits

• Previous
• 1
• 2
• Next